Cholesterol :: Cholesterol drug torcetrapib fails to reduce coronary risk
Cleveland Clinic researchers report that the drug torcetrapib, despite raising high density lipoprotein cholesterol (HDL) or the “good” cholesterol by more than 60%, did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe.